Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Search results for: juvenile idiopathic arthritis
FDA Approves Sarilumab for pJIA
The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.
Pediatric Clinical Year in Review: 2023
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.
Growing Up
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
Changing Treatment Patterns for Patients with JIA
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report
Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.
Management of Adults with JIA: Uveitis, MAS & More
Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.
Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 38
- Next Page »